Matthew David Hellmann
Memorial Sloan Kettering Cancer Center
Affiliation Memorial Sloan Kettering Cancer Center Top Publications Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer (2015) – 8,078 citations Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer (2015) – 6,327 citations Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors (2017) – 5,752 citations Immune-Related Adverse Events Associated with ... <a title="Matthew David Hellmann" class="read-more" href="https://journalsworld.com/researchers/matthew-david-hellmann/" aria-label="Read more about Matthew David Hellmann">Read more</a>
Read biography ↓Biography, research & contributions
Affiliation
Memorial Sloan Kettering Cancer Center
Top Publications
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer (2015) - 8,078 citations
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer (2015) - 6,327 citations
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors (2017) - 5,752 citations
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade (2018) - 4,936 citations
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types (2019) - 4,468 citations
At a glance
- Full name
- Matthew David Hellmann
- ORCID
- 0000-0002-2670-9777
- OpenAlex ID
- https://openalex.org/A5029805571
Research interests
- Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies, Cancer Genomics and Diagnostics
Research topics
Education
Not yet documented in this profile.
Selected research & further reading
A curated reading list, not a ranking by citation count. References use DOI metadata, matching public scholarly records or authoritative lecture sources.
See the source-linked reading and original works in the research guide above.
Citation & publication trends
Annual counts are not yet available from a verified author record. Explore the research guide above for the work itself; publication and citation totals depend on database coverage.
Source: OpenAlex · Retrieved 2026-10-07. Metrics are database-specific and are not a scientific ranking.
Most-cited linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- 8,078OpenAlex citations
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer ↗2015 · New England Journal of Medicine6,327OpenAlex citations
- 5,752OpenAlex citations
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade ↗2018 · New England Journal of Medicine4,936OpenAlex citations
- 4,468OpenAlex citations
Recent linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer ↗2015 · New England Journal of Medicine
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade ↗2018 · New England Journal of Medicine
Journals published in
No verified record links added yet.
Related publishers
No verified record links added yet.
Institutions
Current verified institution
No verified record links added yet.
Previous institutions
No verified record links added yet.
Awards & honors
Not yet documented in this profile.
Career timeline
Not yet documented in this profile.
Co-authors
No verified record links added yet.
Education & career institution links
No verified record links added yet.
Claim & manage this profile
Are you this researcher? Sign in, provide identity evidence, and request administrator approval. Editing becomes available only after approval.
Sign in to claim this profileSources & data information
Editorial review: 2026-10-07 · Last data update: 2026-10-07 20:43:07
Unknown values are left blank. Linked publications may be a subset of total works. Identity verification, data retrieval and profile ownership are separate checks.